Unknown

Dataset Information

Surgery combined with adenoviral p53 gene therapy for treatment of non-small cell lung cancer: a phase II study.


ABSTRACT:

Objective

To assess the efficacy of radical surgery combined with recombinant adenoviral human p53 (rAd-p53) gene therapy in treatment of resectable non-small cell lung cancer.

Method

A total of 163 patients with resectable NSCLC meeting the inclusion criteria were randomly assigned to two groups: radical surgery alone (S) and radical surgery plus surgical wound surface injection of 2 x 1012 rAd-p53 units (SP). All patients were followed up for at least 3 years for efficacy and safety. Study endpoints were loco-regional recurrence or distant metastasis (Rec-Met) rate as primary endpoints, and progression free survival (PFS), overall survival (OS) and safety assessments as secondary endpoints.

Results

Recurrence or metastasis (Rec/Met) after surgery were 24/

SUBMITTER: Deng B 

PROVIDER: S-EPMC5739798 | biostudies-literature | 2017 Dec

REPOSITORIES: biostudies-literature